Thomas, J., Kamso, M. M., Whittle, S. L., Wells, G. A., Kelly, S. E., Pardo Pardo, J., Tugwell, P., Johnston, R. V., Glennon, V., Ejaredar, M., Thomas, M., Lee, C., Elliott, J., Mokbel, A., Avery, J. C., Grobler, L., Cyril, S., Deardon, R., Akl, E. A., Maxwell, L. J., … Supported by the Cochrane Musculoskeletal Health and Pain Thematic Group (2026). Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis. The Cochrane database of systematic reviews, 7(7), CD013562. https://doi.org/10.1002/14651858.CD013562.pub2
Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis
Previous
Previous
Impact of socioeconomic status on disability in a longitudinal rheumatoid arthritis cohort
Next
Next